Literature DB >> 23213087

Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.

Yuan Chen1, Xiulong Song, Leila Valanejad, Alexander Vasilenko, Vijay More, Xi Qiu, Weikang Chen, Yurong Lai, Angela Slitt, Matthew Stoner, Bingfang Yan, Ruitang Deng.   

Abstract

UNLABELLED: As a canalicular bile acid effluxer, the bile salt export pump (BSEP) plays a vital role in maintaining bile acid homeostasis. BSEP deficiency leads to severe cholestasis and hepatocellular carcinoma (HCC) in young children. Regardless of the etiology, chronic inflammation is the common pathological process for HCC development. Clinical studies have shown that bile acid homeostasis is disrupted in HCC patients with elevated serum bile acid level as a proposed marker for HCC. However, the underlying mechanisms remain largely unknown. In this study, we found that BSEP expression was severely diminished in HCC tissues and markedly reduced in adjacent nontumor tissues. In contrast to mice, human BSEP was regulated by farnesoid X receptor (FXR) in an isoform-dependent manner. FXR-α2 exhibited a much more potent activity than FXR-α1 in transactivating human BSEP in vitro and in vivo. The decreased BSEP expression in HCC was associated with altered relative expression of FXR-α1 and FXR-α2. FXR-α1/FXR-α2 ratios were significantly increased, with undetectable FXR-α2 expression in one third of the HCC tumor samples. A similar correlation between BSEP and FXR isoform expression was confirmed in hepatoma Huh7 and HepG2 cells. Further studies showed that intrahepatic proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), were significantly elevated in HCC tissues. Treatment of Huh7 cells with IL-6 and TNF-α resulted in a marked increase in FXR-α1/FXR-α2 ratio, concurrent with a significant decrease in BSEP expression.
CONCLUSION: BSEP expression is severely diminished in HCC patients associated with alteration of FXR isoform expression induced by inflammation. Restoration of BSEP expression through suppressing inflammation in the liver may reestablish bile acid homeostasis.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23213087      PMCID: PMC3608797          DOI: 10.1002/hep.26187

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Endogenous bile acids as carcinogens.

Authors:  Peter L M Jansen
Journal:  J Hepatol       Date:  2007-06-14       Impact factor: 25.083

2.  Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.

Authors:  Baohong Wang; Deying Chen; Yu Chen; Zhenhua Hu; Min Cao; Qing Xie; Yanfei Chen; Jiali Xu; Shusen Zheng; Lanjuan Li
Journal:  J Proteome Res       Date:  2012-01-18       Impact factor: 4.466

3.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.

Authors:  Insook Kim; Keiichirou Morimura; Yatrik Shah; Qian Yang; Jerrold M Ward; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

4.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

5.  Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry.

Authors:  Hongcui Cao; Haijun Huang; Wei Xu; Deying Chen; Jiong Yu; Jun Li; Lanjuan Li
Journal:  Anal Chim Acta       Date:  2011-02-23       Impact factor: 6.558

6.  Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling.

Authors:  Andrew M Anisfeld; Heidi R Kast-Woelbern; Hans Lee; Yanqiao Zhang; Florence Y Lee; Peter A Edwards
Journal:  J Lipid Res       Date:  2004-12-16       Impact factor: 5.922

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

8.  Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.

Authors:  Rajani Kaimal; Xiulong Song; Bingfang Yan; Roberta King; Ruitang Deng
Journal:  J Pharmacol Exp Ther       Date:  2009-04-15       Impact factor: 4.030

9.  Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.

Authors:  Reid M Huber; Kathleen Murphy; Bowman Miao; John R Link; Mark R Cunningham; Mark J Rupar; Paul L Gunyuzlu; Thomas F Haws; Altaf Kassam; Francoise Powell; Gregory F Hollis; Peter R Young; Ranjan Mukherjee; Timothy C Burn
Journal:  Gene       Date:  2002-05-15       Impact factor: 3.688

Review 10.  Chronic liver inflammation and hepatocellular carcinoma: persistence matters.

Authors:  Achim Weber; Yannick Boege; Florian Reisinger; Mathias Heikenwälder
Journal:  Swiss Med Wkly       Date:  2011-05-10       Impact factor: 2.193

View more
  24 in total

1.  Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis.

Authors:  Guoxiang Xie; Xiaoning Wang; Fengjie Huang; Aihua Zhao; Wenlian Chen; Jingyu Yan; Yunjing Zhang; Sha Lei; Kun Ge; Xiaojiao Zheng; Jiajian Liu; Mingming Su; Ping Liu; Wei Jia
Journal:  Int J Cancer       Date:  2016-06-17       Impact factor: 7.396

2.  Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor.

Authors:  Xiulong Song; Yuan Chen; Leila Valanejad; Rajani Kaimal; Bingfang Yan; Matthew Stoner; Ruitang Deng
Journal:  J Lipid Res       Date:  2013-09-03       Impact factor: 5.922

3.  FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.

Authors:  Jun Yao; Chun-Suo Zhou; Xiong Ma; Bai-Qing Fu; Li-Sheng Tao; Miao Chen; Ya-Ping Xu
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 4.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

Review 5.  FXR and liver carcinogenesis.

Authors:  Xiong-fei Huang; Wei-yu Zhao; Wen-dong Huang
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

6.  Estrogen and Estrogen Receptor-α-Mediated Transrepression of Bile Salt Export Pump.

Authors:  Yuan Chen; Alex Vasilenko; Xiulong Song; Leila Valanejad; Ruchi Verma; Sangmin You; Bingfang Yan; Stephanie Shiffka; Leeza Hargreaves; Christina Nadolny; Ruitang Deng
Journal:  Mol Endocrinol       Date:  2015-02-12

Review 7.  Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations.

Authors:  Carol J Soroka; James L Boyer
Journal:  Mol Aspects Med       Date:  2013-05-15

8.  Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy.

Authors:  Xiulong Song; Alexander Vasilenko; Yuan Chen; Leila Valanejad; Ruchi Verma; Bingfang Yan; Ruitang Deng
Journal:  Hepatology       Date:  2014-05-19       Impact factor: 17.425

9.  Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver.

Authors:  Vijay R More; Qiuqiong Cheng; Ajay C Donepudi; David B Buckley; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2013-03-05       Impact factor: 3.922

10.  Dysregulation of Δ4-3-oxosteroid 5β-reductase in diabetic patients: Implications and mechanisms.

Authors:  Leila Valanejad; Mwlod Ghareeb; Stephanie Shiffka; Christina Nadolny; Yuan Chen; Liangran Guo; Ruchi Verma; Sangmin You; Fatemeh Akhlaghi; Ruitang Deng
Journal:  Mol Cell Endocrinol       Date:  2017-10-09       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.